David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn:
“Great to spend the weekend with my Chinese colleagues/friends discussing the latest strategies in lung cancer!
Thrilled about FLAURA2 as the new 1st-line standard for EGFRm patients and so impressed with the innovative new drugs from China and recently presented at ESMO.”
You cal also read: FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Overall Survival Across Prognostic Subgroups in EGFR-Mutated Advanced NSCLC — Presented at ESMO 2025
